High-dose simvastatin and rhabdomyolysis

被引:16
作者
Wratchford, P
Ponte, CD
机构
[1] W Virginia Univ, Sch Pharm, Robert C Byrd Hlth Sci Ctr, Dept Clin Pharm, Morgantown, WV 26506 USA
[2] W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr, Dept Clin Pharm, Morgantown, WV 26506 USA
[3] W Virginia Univ, Sch Pharm, Robert C Byrd Hlth Sci Ctr, Dept Family Med, Morgantown, WV 26506 USA
[4] W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr, Dept Family Med, Morgantown, WV 26506 USA
关键词
D O I
10.1093/ajhp/60.7.698
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
[No abstract available]
引用
收藏
页码:698 / 700
页数:3
相关论文
共 11 条
[1]   EXPANDED CLINICAL-EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS .1. EFFICACY IN MODIFYING PLASMA-LIPOPROTEINS AND ADVERSE EVENT PROFILE IN 8245 PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA [J].
BRADFORD, RH ;
SHEAR, CL ;
CHREMOS, AN ;
DUJOVNE, C ;
DOWNTON, M ;
FRANKLIN, FA ;
GOULD, AL ;
HESNEY, M ;
HIGGINS, J ;
HURLEY, DP ;
LANGENDORFER, A ;
NASH, DT ;
POOL, JL ;
SCHNAPER, H .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (01) :43-49
[2]   Safety profiles for the HMG-CoA reductase inhibitors - Treatment and trust [J].
Davidson, MH .
DRUGS, 2001, 61 (02) :197-206
[3]  
FERRI FF, 2001, PRACTICAL GUIDE CARE, P800
[4]   Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin [J].
Mogyorósi, A ;
Bradley, B ;
Showalter, A ;
Schubert, ML .
JOURNAL OF INTERNAL MEDICINE, 1999, 246 (06) :599-602
[5]   FDA adverse event reports on statin-associated rhabdomyolysis [J].
Omar, MA ;
Wilson, JP .
ANNALS OF PHARMACOTHERAPY, 2002, 36 (02) :288-295
[6]   Rhabdomyolysis and HMG-CoA reductase inhibitors [J].
Omar, MA ;
Wilson, JP ;
Cox, TS .
ANNALS OF PHARMACOTHERAPY, 2001, 35 (09) :1096-1107
[7]  
Pedersen TR, 1998, CIRCULATION, V98, P451
[8]  
Sauret JM, 2002, AM FAM PHYSICIAN, V65, P907
[9]  
Vanholder R, 2000, J AM SOC NEPHROL, V11, P1553, DOI 10.1681/ASN.V1181553
[10]   Rhabdomyolysis [J].
Visweswaran, P ;
Guntupalli, J .
CRITICAL CARE CLINICS, 1999, 15 (02) :415-+